U.S. AGENT · SERVICE DETAILS

U.S. agent services

U.S. agent designation, FDA liaison, inspection arrangements for communication and agent information maintenance support are provided to drug facilities outside the country that are legally required to register.

Applicability and scope depend on the product, your business role and the agreed engagement. The service does not constitute FDA approval or certification.

SERVICE OVERVIEW

What does this service help with?

Off-shore pharmaceutical facilities should check registration and U.S. obligation in relation to actual activities and United States import arrangements. We first identify the facility, the current agent and the FDA contact details, then specify, replace, daily contact and maintain the range.

WHO MAY NEED IT

Who should consider this service?

U.S. agent is required to designate offshore facilities in the FDA pharmaceutical facility register, including preparations or API production facilities that meet the applicable conditions. The mere possession of brand names, Labler Code or DMF does not directly establish the need for the same facility agent.

SCOPE & APPROACH

What we typically discuss

Identify information gaps before agreeing on documentation and responsibilities.

01

Designation and replacement of agents

Checking facilities, registrations, agent information and authorization arrangements to assist in the preparation of U.S. agent designations or changes and applicable information checks.

02

FDA Daily Liaison

Receiving, transmitting and responding to FDA communications and related imports of medicines within the identified service, designating internal handlers and recording the status of processing.

03

Inspection arrangements and information maintenance

Assisting the FDA in communicating with facilities inspection arrangements, maintaining proxy contacts and liaison mechanisms; Specific inspection responses, modifications and declaration support are confirmed separately.

GET READY

What to prepare before contacting us

If documents are incomplete, share the product and current stage first. You can provide the remaining details later.

  • Legal name of the facility, actual address, D—U—N—S and actual operations
  • Registration records of existing pharmaceutical facilities, established agents and changes to be processed
  • Business leaders and FDA focal points, daily and emergency contacts
  • Existing FDA letters, inspection notifications or import-related issues (if any)
HOW TO START

From initial review to engagement

STEP 01

Confirmation of applicable facilities and current status

Reconciling business activities, facilities registration and existing agency arrangements.

STEP 02

Contractual duties and liaison mechanisms

Identification of representative designations, authorizations, correspondence processing, emergency promotions and cost ranges.

STEP 03

Connect registration to agent records

Process applicable registration information according to the current FDA process and check the submission and confirmation of results.

STEP 04

Ongoing liaison and maintenance

Follow-in letters and inspection arrangements; When contact, agent or facility information is replaced, applicable updates are checked in a timely manner.

The pharmaceutical facility U.S. agent has a different role from the label clearance, the DMF authorized representative, the importer and the submitting party. Designated agents are not a substitute for the quality of the business, the registration of listings, legal listings and other applicable obligations.

TIMING & FEES

Timing and fees

Information reviewed:Fee period: FDA rules checked November 5, 2026. Verify charges for the applicable date or fiscal year.

Timing and preparation

Document preparation

The facilities, existing agents, registration status, authorization and effective contact details are checked first to arrange for designation or replacement and contact handover.

FDA processing

(a) The appointment, replacement and maintenance time is affected by the account, the original record, the consent of the agent and the integrity of the information; Daily contact is agreed on a service agreement and there is no commitment to resolve all FDA issues within a fixed number of days.

Fee breakdown

FDA fees

U.S. agent service fees are agreed between the parties and are not user fees charged by the FDA for agent services; The registration, application or other application of the FDA for the facility on whose behalf the facility is represented is separately charged.

Service fees

Consulting and filing are quoted separately from FDA fees, based on the number of products, completeness of the records, work scope, response rounds and service term.

Other possible costs

Testing, translation, software and other third-party work are quoted separately where needed.

START WITH YOUR PRODUCT

Confirm the facility and arrange for U.S. agent and liaison maintenance.

Provision of facilities, current registration and representation arrangements, checking of applicable obligations and matters to be addressed.